-
公开(公告)号：US20080113015A1
公开(公告)日：2008-05-15
申请号：US11569514
申请日：2005-05-24
IPC分类号： A61K9/127 , A61K38/16 , A61K31/715 , A61P43/00
CPC分类号： A61K9/1271
摘要： The present invention relates to liposomes for drug delivery, wherein a liposome includes molecules of at least one desired drug distributed within an aqueous phase in the interior of the liposome and wherein the liposome further includes molecules of the same or of another drug attached to either or both sides of the liposomal membrane. More specifically, the invention relates to liposomes, wherein at least a part of the molecules of a desired drug bear a functional group that is reactive with a functional group present in at least one lipid fraction, and wherein the drug is covalently linked to the membrane lipids by chemical bonding, e.g. by ester bonding of a hydroxyl group of a lipid molecule and an acidic residue of the drug. In a preferred embodiment, the desired drug is a glycoprotein such as erythropoietin. The invention further relates to a method of manufacture of said liposomes and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及用于药物递送的脂质体，其中脂质体包括分布在脂质体内部的水相内的至少一种所需药物的分子，并且其中所述脂质体还包括与所述脂质体或其它药物相连接的分子， 脂质体膜两侧。 更具体地，本发明涉及脂质体，其中所需药物的至少一部分分子具有与存在于至少一种脂质部分中的官能团反应的官能团，并且其中所述药物与膜共价连接 脂质通过化学键合，例如 通过脂质分子的羟基和药物的酸性残基的酯键合。 在优选的实施方案中，所需药物是糖蛋白，例如红细胞生成素。 本发明还涉及制备所述脂质体的方法和含有它们的药物组合物。
-
公开(公告)号：US07595049B2
公开(公告)日：2009-09-29
申请号：US10485525
申请日：2002-09-09
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/505 , C07K16/1063 , C07K2317/21 , C07K2317/34 , C12N2740/16122
摘要： The present invention relates to neutralizing anti-HIV-1 antibodies, particularly to mAb 4E10-IgG1, which has an HIV-1 neutralizing potency comparable to the one of mAb 2F5 and 2G12. 4E10-IgG1 binds to a novel conserved epitope (NWFDIT) C-terminal of the ELDKWA epitope recognized by 2F5.1 appears that both epitopes are cryptic epitopes within a region that may be accessible in a virus-cell fusion intermediate state only. 4E10-IgG1 potently neutralizes tissue culture adapted strains but also primary isolates of different clades, including A, B, C, D, and E, inclusing viruses that were found to be resistant to 2F5. None of the tested isolates was resistant to both anti-gp41-antibodies. The invention therefore also relates to peptides containing the 4E10 epitope and to compositions made thereof, as well as to anti-idiotypic antibodies that are reactive with the paratope of 4E10-IgG1, to compositions containing an antiidiotypic antibody optionally in combination with a peptide containing the 4E10 epitope, and to anti-HIV-1 compositions comprising 4E10-IgG1, optionally in combination with another neutralizing antibody such as 2F5 and/or 2G12.
摘要翻译： 本发明涉及中和抗HIV-1抗体，特别是抗mAb 4E10-IgG1，其具有与mAb 2F5和2G12中的一种相当的HIV-1中和效力。 4E10-IgG1与2F5.1识别的ELDKWA表位的新保守表位（NWFDIT）C-末端结合似乎是两个表位是仅在病毒 - 细胞融合中间状态可以接近的区域内的隐性表位。 4E10-IgG1有力地中和组织培养适应菌株，也可以中和不同进化枝的初级分离物，包括A，B，C，D和E，包括被发现对2F5有抗性的病毒。 没有一个测试的分离株对抗gp41-抗体均有抗性。 因此，本发明还涉及含有4E10表位的肽及其制备的组合物，以及与4E10-IgG1的相互作用反应的抗独特型抗体，所述组合物含有抗独立型抗体，所述组合物任选地与含有 4E10表位，以及包含4E10-IgG1的抗HIV-1组合物，任选地与另一种中和抗体如2F5和/或2G12组合。
-
公开(公告)号：US20050080240A1
公开(公告)日：2005-04-14
申请号：US10501726
申请日：2003-01-17
CPC分类号： C07K16/4225 , A61K39/00 , A61K2039/505
摘要： The invention relates to Ab2-type anti-idiotypic antibodies and fragments thereof which mimic HVI-1 epitopes that are otherwise cryptic to the immune system and which antibodies or fragments thereof are directed against potently neutralizing anti-HIV-1 antibodies. The invention further relates to a hybridoma cell line 3H6 expressing the anti-idiotypic antibody and to pharmaceutical compositions containing the antibody or fragment thereof. The invention also relates to HIV-1 neutralizing Ab3-type antibodies elicited upon administration of the Ab2-type anti-idiotypic antibody or fragment thereof and to pharmaceutical compositions containing them. The invention also relates to the use of the present antibodies or fragments thereof as screening tools or as diagnostic or therapeutic agents.
摘要翻译： 本发明涉及Ab2型抗独特型抗体及其片段，其模拟HVI-1表位，否则其对于免疫系统是隐秘的，哪些抗体或其片段针对有效中和抗HIV-1抗体。 本发明还涉及表达抗独特型抗体的杂交瘤细胞系3H6和含有抗体或其片段的药物组合物。 本发明还涉及在施用Ab2型抗独特型抗体或其片段时引发的HIV-1中和Ab3型抗体以及含有它们的药物组合物。 本发明还涉及本发明的抗体或其片段作为筛选工具或诊断或治疗剂的用途。
-
4.发明授权Anti-idiotypic monoclonal antibody reactive with HIV neutralizing antibody 2F5 失效与HIV中和抗体2F5反应的抗独特型单克隆抗体公开(公告)号：US07625566B2
公开(公告)日：2009-12-01
申请号：US10501726
申请日：2003-01-17
CPC分类号： C07K16/4225 , A61K39/00 , A61K2039/505
摘要： The invention relates to Ab2-type anti-idiotypic antibodies and fragments thereof which mimic HVI-1 epitopes that are otherwise cryptic to the immune system and which antibodies or fragments thereof are directed against potently neutralizing anti-HIV-1 antibodies. The invention further relates to a hybridoma cell line 3H6 expressing the anti-idiotypic antibody and to pharmaceutical compositions containing the antibody or fragment thereof. The invention also relates to HIV-1 neutralizing Ab3-type antibodies elicited upon administration of the Ab2-type anti-idiotypic antibody or fragment thereof and to pharmaceutical compositions containing them. The invention also relates to the use of the present antibodies or fragments thereof as screening tools or as diagnostic or therapeutic agents.
摘要翻译： 本发明涉及Ab2型抗独特型抗体及其片段，其模拟HVI-1表位，否则其对于免疫系统是隐秘的，哪些抗体或其片段针对有效中和抗HIV-1抗体。 本发明还涉及表达抗独特型抗体的杂交瘤细胞系3H6和含有抗体或其片段的药物组合物。 本发明还涉及在施用Ab2型抗独特型抗体或其片段时引发的HIV-1中和Ab3型抗体以及含有它们的药物组合物。 本发明还涉及本发明的抗体或其片段作为筛选工具或诊断或治疗剂的用途。
-
公开(公告)号：US20050084969A1
公开(公告)日：2005-04-21
申请号：US10497015
申请日：2002-11-26
IPC分类号： C12N15/09 , A61K38/22 , A61P7/00 , A61P7/06 , C07K14/505 , C12N5/10 , C12N15/85 , C12N15/90 , C12P21/02 , C12N5/06
CPC分类号： C07K14/505 , A61K2121/00 , C12N15/85 , C12N15/90 , C12N15/907 , C12N2840/203 , C12P21/02
摘要： The invention relates to a method for producing a transformed eukaryotic host cell which expresses a recombinant polypeptide of interest which method comprises introducing into a eukaryotic host cell: (a) a first polynucleotide vector which comprises (i) a first nucleotide sequence which encodes a recombinant polypeptide of interest, and (ii) a second nucleotide sequence encoding a selectable marker, which second nucleotide sequence is amplified when the host cell is contacted with a selection agent; and (b) a second polynucleotide vector having essentially the same nucleotide sequence as the first polynucleotide vector except that the second nucleotide sequence is replaced with a third nucleotide sequence which encodes a different selectable marker; the first polynucleotide vector and second polynucleotide vector being stably integrated into the genome of the host cell.
摘要翻译： 本发明涉及用于产生表达重组感兴趣的多肽的转化真核宿主细胞的方法，所述方法包括将真核宿主细胞导入：（a）第一多核苷酸载体，其包含（i）第一核苷酸序列，其编码重组 多肽，和（ii）编码选择性标记的第二核苷酸序列，当宿主细胞与选择剂接触时，第二核苷酸序列被扩增; 和（b）第二多核苷酸载体，其具有与第一多核苷酸载体基本上相同的核苷酸序列，除了第二核苷酸序列被编码不同选择标记的第三核苷酸序列替代; 第一多核苷酸载体和第二多核苷酸载体稳定整合到宿主细胞的基因组中。
-
公开(公告)号：US20050069979A1
公开(公告)日：2005-03-31
申请号：US10497123
申请日：2002-11-26
IPC分类号： C12N15/09 , C07K14/505 , C12N5/10 , C12P21/02 , C12N15/85
CPC分类号： C12P21/02 , C07K14/505 , C12N2500/34 , C12N2500/76 , C12N2500/92 , C12N2510/02
摘要： The invention provides a method for producing a recombinant polypeptide of interest which method comprises: (a) providing a host cell which comprises a nucleotide sequence which encodes the recombinant polypeptide of interest and which directs expression of the recombinant polypeptide of interest in the host cell; (b) providing a serum-free culture medium which comprises (i) water, a plant-derived peptone, an osmolality regulator, a buffer, an energy source, at least one amino acid, a lipid source or precursor, a source of iron, non-ferrous metal ions and optionally one or more vitamins and cofactors; and (ii) does not contain any full-length polypeptides; and (c) culturing the host cell in the culture medium under conditions that allow for expression of the recombinant polypeptide of interest.
摘要翻译： 本发明提供了一种用于产生感兴趣的重组多肽的方法，所述方法包括：（a）提供宿主细胞，其包含编码所述重组多肽的核苷酸序列，其指导所述重组感兴趣多肽在所述宿主细胞中的表达; （b）提供无血清培养基，其包含（i）水，植物来源的蛋白胨，渗透压调节剂，缓冲液，能量源，至少一种氨基酸，脂质源或前体，铁源 ，有色金属离子和任选的一种或多种维生素和辅因子; 和（ii）不含任何全长多肽; 和（c）在允许感兴趣的重组多肽表达的条件下在培养基中培养宿主细胞。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.033 秒)
